Latest News - Regeneron Pharmaceuticals
Top Corporates Hub
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc. (REGN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
04.09.2025 16:03
Get the latest insights on Regeneron's pipeline, EYLEA HD growth
Merck KGaA, Darmstadt, Germany, Appoints David Weinreich as New Global Head of R&D and Chief Medical Officer for Healthcare Business Sector
02.09.2025 13:00
DARMSTADT, Germany, September 02, 2025--Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced the appointment of David Weinreich, MD, MBA, as Global Head of R&D and Chief Medical Officer for its Healthcare business sector.
Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib
25.08.2025 12:00
- Immuneering to evaluate atebimetinib in combination with olomorasib in planned Phase 2 trial in patients with advanced non-small cell lung cancer – CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced a clinical supply agreement with Eli Lilly and Company (NYSE:LLY) for its second-generation KRAS G12C inhibitor, olomorasib (LY3537982). The supply agreement supports
Will EXEL's Share Repurchase Program Boost Value for Investors?
19.08.2025 13:33
Exelixis repurchases shares for $796M, aiming to boost EPS and shareholder value through 2025.
Students Earn Top Awards at 42nd Annual Research Science Institute at MIT
14.08.2025 10:05
MCLEAN, Va., Aug. 14, 2025 (GLOBE NEWSWIRE) -- The Center for Excellence in Education (CEE) is pleased to announce the award winners for oral and written presentations chosen from 100 participants by an eminent panel of judges at the 42nd annual Research Science Institute (RSI), sponsored in collaboration with the Massachusetts Institute of Technology (MIT). Each of the award winners received $1,000 scholarship awards from Regeneron Pharmaceuticals, Inc. Top 5 Written Research: Jayveer Kochhar,
Here’s Why You Should Consider Buying Regeneron Pharma (REGN)’s Shares
13.08.2025 13:05
Parnassus Investments, an investment management firm that focuses on owning a concentrated portfolio of U.S. large-cap stocks, released its Parnassus Value Equity Fund second-quarter 2025 investor letter. The full letter is available for download here. For the second quarter of 2025, the fund reported a net return of 7.24%, outperforming its benchmark, the Russell 1000 […]
5 Insightful Analyst Questions From Regeneron’s Q2 Earnings Call
13.08.2025 04:14
Regeneron’s second quarter was marked by robust growth in key products, which the company attributed to the strong commercial performance of Dupixent, Libtayo, and the launch of EYLEA HD. CEO Leonard Schleifer highlighted that worldwide net product sales for Dupixent increased by 21% and Libtayo by 25% at constant exchange rates, while EYLEA HD saw a 29% rise in the U.S. compared to the prior year. Management pointed to broad-based demand across new indications and geographies, as well as positi
REGN Q2 Deep Dive: New Indications and Pipeline Progress Offset EYLEA Challenges
13.08.2025 03:43
Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 3.6% year on year to $3.68 billion. Its non-GAAP profit of $12.89 per share was 52.9% above analysts’ consensus estimates.
Sanofi halts Praluent supply in China due to limited availability
12.08.2025 10:36
Investing.com -- Sanofi (NASDAQ:SNY) announced on Tuesday that it has stopped supplying Praluent in China due to limited availability of the popular cholesterol medication.
Regeneron Reveals The Regeneron Prize For Creative Innovation 2025 Winners
12.08.2025 00:20
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) awarded the 13th annual Regeneron Prize for Creative Innovation to early-career biomedical researchers who displayed exceptional innovation. The winners for 2025 are Dr. Alissandra L. Hillis, a postdoctoral fellow at MIT, and Mr. Sreekar […]
BMO Capital Lifts PT on Regeneron Pharmaceuticals (REGN) Stock, Keeps Outperform
08.08.2025 03:48
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Most Undervalued Long Term Stocks to Buy According to Hedge Funds. On August 4, BMO Capital lifted the price target on the company’s stock to $640 from $600, while keeping an “Outperform” rating, as reported by The Fly. As per the analyst, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)’s healthy Q2 2025 […]
Regeneron: Rapidly Decreasing Importance Of Eylea
01.08.2025 16:05
Regeneron Pharmaceuticals delivered strong Q2 results and made net progress with its commercial portfolio and pipeline. Click here to read why REGN is a Buy.
Regeneron Pharmaceuticals, Inc. (REGN) Q2 2025 Earnings Call Transcript
01.08.2025 13:46
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q2 2025 Earnings Conference Call August 1, 2025 8:30 AM ETCompany ParticipantsChristopher R.
Regeneron (REGN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
01.08.2025 13:30
Although the revenue and EPS for Regeneron (REGN) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Regeneron's Pipeline Hit By Catalent Delays, But Dupixent Shines
01.08.2025 13:22
On Friday, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported second-quarter adjusted earnings of $12.89 per share, up 12% year-over-year, beating the consensus of $8.57. The company reported sales of $3.68 billion, up 4% year over year, beating the consensus of $3.29 billion. In the second quarter, U.S. net sales for Eylea HD and Eylea decreased 25% year-over-year to $1.15 billion, including $393 million from Eylea HD and $754 million from Eylea. Also Read: Regeneron’s Obesity Trial With Nov
Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping.
01.08.2025 13:16
U.S. sales of Eylea HD and Eylea, treatments for eye conditions like wet age-related macular degeneration, decreased 25% in the quarter from last year
Regeneron posts better-than-expected Q2 results, downplays tariff impact
01.08.2025 12:21
(Reuters) -Regeneron topped Wall Street estimates for second-quarter results on Friday, on robust demand for its blockbuster eczema drug Dupixent, and said it does not expect a material impact from tariffs on imports from the European Union. As the company gains clarity on details of the agreement and other potential tariffs, CEO Leonard Schleifer said the 15% duties were not expected to have a material impact. Investors have set a high bar for Regeneron and French partner Sanofi's Dupixent, one of the U.S. drugmaker's growth drivers.
Regeneron shares edge higher as second quarter earnings surpass estimates
01.08.2025 11:46
Investing.com -- Regeneron Pharmaceuticals, Inc. reported second-quarter earnings that significantly exceeded analyst expectations, with adjusted earnings per share reaching $12.89 compared to the $8.43 consensus estimate. Revenue also beat forecasts, coming in at $3.68 billion versus the expected $3.28 billion.
Regeneron (REGN) Tops Q2 Earnings and Revenue Estimates
01.08.2025 11:45
Regeneron (REGN) delivered earnings and revenue surprises of +60.52% and +9.91%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Regeneron: Q2 Earnings Snapshot
01.08.2025 10:41
TARRYTOWN, N.Y. (AP) — Regeneron Pharmaceuticals Inc. REGN) on Friday reported second-quarter earnings of $1.39 billion. The Tarrytown, New York-based company said it had profit of $12.81 per share.